Statement re. Suspension

    RNS Number : 8800K
  Norwood Immunology Ld
  30 December 2008
   

    NORWOOD IMMUNOLOGY LIMITED 

    Temporary suspension of trading in securities

    Norwood Immunology Limited and its subsidiaries ("Norwood Immunology" or the "Group") (AIM:NIM), the Group focused on stem cell
therapies, the rejuvenation and repair of the immune system and the development of virosomal vaccines, today announces that it has requested
trading in its AIM securities to be suspended as Norwood Immunology will be unable to publish its Annual Report and Accounts ("Accounts")
for the year ended 30 June 2008 by 31 December 2008.

    The Board is working closely with its auditors in Australia to prepare the Accounts and expects to publish the Accounts during the week
commencing 5 January 2009.

    A further announcement will be made in due course.

    For further information please contact:

 Norwood Immunology Limited
 Richard Williams, Chief Executive Officer         +44 (0)7860 295153

 KBC Peel Hunt Ltd (Nominated Adviser and Broker)  +44 (0)207 418 8900
 Capel Irwin
 David Anderson


This information is provided by RNS
The company news service from the London Stock Exchange
 
  END 
 
SRSFKKKBKBDDOBN

Norwood Immunology (LSE:NIM)
과거 데이터 주식 차트
부터 4월(4) 2024 으로 5월(5) 2024